Schmidt U J, Trzenschik K, Abendroth K, Graner H, Ansorg A
Z Alternsforsch. 1978;33(2):173-83.
16 patients with a Paget's disease at the age of 51--80 years were treated by synthetic salmon calcitonine in a dosis of 20 mcg (80 MRCU/die). 14 patients could be observed for a longer time. In all cases there was a statically significant decrease of the increased alkaline serum phosphatase. The excretion of hydroxyproline in the collected urine had a decreasing tendency. Other laboratory parameters as calcium, phosphatase and acid phosphatase in the serum and the excretion of calcium and phosphate in the urine were not significant influenced by therapy. The patients felt subjective a clear improvement of the bone pains. After a six month-treatment the dosis was reduced (each 2--7 days 20 mcg salmon calcitonin sc). There was observed a rebehaviour of the subjective symptoms and an increase of the alkaline serum phosphatase, which did not reach the unitial values before the beginning of treatment. Calcitonine is an effective substance for the treatment of an active Paget's disease.
16例年龄在51至80岁的佩吉特病患者接受了剂量为20微克(80 MRCU/日)的合成鲑鱼降钙素治疗。14例患者得到了较长时间的观察。在所有病例中,血清碱性磷酸酶升高均有统计学意义的下降。收集尿液中羟脯氨酸的排泄有下降趋势。血清中的其他实验室参数如钙、磷酸酶和酸性磷酸酶以及尿液中钙和磷的排泄未受治疗的显著影响。患者主观感觉骨痛明显改善。经过6个月的治疗后,剂量减少(每2至7天皮下注射20微克鲑鱼降钙素)。观察到主观症状复发以及血清碱性磷酸酶升高,但未达到治疗开始前的初始值。降钙素是治疗活动性佩吉特病的有效物质。